Last reviewed · How we verify

Ketotifen/Indomethacin — Competitive Intelligence Brief

Ketotifen/Indomethacin (Ketotifen/Indomethacin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mast cell stabilizer / NSAID combination. Area: Allergy / Inflammation.

phase 3 Mast cell stabilizer / NSAID combination H1 receptor, mast cell stabilization, COX-1/COX-2 Allergy / Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Ketotifen/Indomethacin (Ketotifen/Indomethacin) — Sen-Jam Pharmaceutical. Ketotifen is a mast cell stabilizer and H1-receptor antagonist, while indomethacin is a non-selective NSAID that inhibits cyclooxygenase, together reducing allergic inflammation and pain.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Ketotifen/Indomethacin TARGET Ketotifen/Indomethacin Sen-Jam Pharmaceutical phase 3 Mast cell stabilizer / NSAID combination H1 receptor, mast cell stabilization, COX-1/COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mast cell stabilizer / NSAID combination class)

  1. Sen-Jam Pharmaceutical · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketotifen/Indomethacin — Competitive Intelligence Brief. https://druglandscape.com/ci/ketotifen-indomethacin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: